After accumulating $86 billion in global sales, Amgen is still trying to keep Enbrel biosimilars off the market, Sandoz ...

In a development landscape as extensive as obesity, we think Pfizer could be better served by looking outside,' Stifel ...

The government is fighting in court for a plan to cut spending on overhead research costs for grantees. Primate centers fear ...

Commerce Secretary Howard Lutnick has indicated more specific timelines as to when pharma tariffs could surface, noting they ...

Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment to lower cholesterol. The experimental gene editing therapy cut bad ...

Under the 11-page 'roadmap' outlined Thursday, the goal is for animal testing to become 'the exception rather than the norm' ...

Scientists develop STITCHR, a retrotransposon-based gene editing tool, by Omar Abudayyeh (Mass General Brigham) and Jonathan ...

It’s a biotech environment without many good choices. Even before President Donald Trump’s tariff announcement pushed stock ...

Alzheon's valiltramiprosate (ALZ-801) fails Phase 3 trial in Alzheimer's patients with APOE4 gene copies, showing no ...

After 17 years at Genentech, Ira Mellman is joining the Parker Institute for Cancer Immunotherapy as president of research.

VC execs write to Sen. Cassidy about FDA staffing concerns, citing delays & uncertainties due to loss of experienced staff & ...

Trump signals imminent pharma tariffs, with experts including Mollie Sitkowski of Faegre Drinker suggesting 25% levy possible ...